Hepatitis B Virus News and Research

RSS

Pegylated interferon alfa-2b offers the best treatment option for people with chronic hepatitis B infection

Harry Janssen (Erasmus University Medical Centre, Rotterdam, Netherlands) and colleagues assessed whether combination treatment with pegylated interferon alfa-2b and the antiviral agent lamivudine was more efficacious in treating chronic hepatitis B infection than pegylated interferon alfa-2b therapy alone.

7 Jan 2005

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Results from a large international clinical study reported in this week's issue of The Lancet showed that peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B. The investigator-initiated study is the largest clinical trial to date with peginterferon alfa-2b therapy for chronic hepatitis B.

7 Jan 2005

Instead of chemotherapy, drugs that influence the X protein's behavior might become an alternative cancer therapy

Identifying the link between chronic hepatitis B infection and liver cancer may one day help cancer patients sidestep the poison of chemotherapy, a Purdue University study suggests.

13 Dec 2004

A new study has found fatty liver disease in nearly one third of American adults in a large urban population sample

The prevalence of the disease varied significantly among ethnic groups. Hispanics had a higher prevalence than whites, while blacks had a lower prevalence than whites.

8 Dec 2004

Eisai In-licenses Anti-hepatitis B Agent clevudine From Bukwang Pharm

Eisai Co., Ltd. announced today that the Company has in-licensed an anti-hepatitis B agent (generic name: clevudine) from Bukwang Pharm (Headquarters, Seoul, South Korea, President: Sung-Koo Lee).

16 Nov 2004

Hep C and HIV among injecting drug users in London are higher than expected

Levels of hepatitis C virus and HIV among injecting drug users in London are higher than expected, according to a study published online by the BMJ.

14 Nov 2004

Prevalence of occult HBV in hemodialysis patients is 4 to 5 times higher than standard HBsAg testing would suggest

Some kidney dialysis patients contract hepatitis B virus (HBV) during the course of their treatment, possibly from other members of the dialysis population with occult HBV.

8 Nov 2004

Britain should adopt universal hepatitis B immunisation

The United Kingdom is one of the few developed countries that have not implemented universal immunisation. Because the burden of hepatitis B was low and individual rights were considered paramount, a policy of selective immunisation of high-risk groups, such as health care workers, homosexual men, and drug addicts, has been followed.

5 Nov 2004

New approaches for the treatment of chronic hepatitis C

Data from two ongoing studies testing new approaches for the treatment of chronic hepatitis C was presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) this afternoon.

1 Nov 2004

Pegasys with ribavirin combo may best for reducing hepatitis C viral levels

Interim study results indicate a certain drug combination treatment may suppress the hepatitis C virus more quickly than another.

1 Nov 2004

Routine screening of blood samples would reduce the risk of disease transmission among transplant recipients

Results of a study in this week’s issue of THE LANCET suggest that routine screening of blood samples to detect viral RNA among organ and tissue donors who do not have obvious signs of clinical disease would reduce the risk of disease transmission among transplant recipients.

29 Oct 2004

Hepatitis C infection increases likelihood of developing non-Hodgkin's lymphoma significantly

Patients infected with the hepatitis C virus (HCV) are six times as likely to develop non-Hodgkin's lymphoma (NHL) than individuals that are virus free, according to research presented at the Third Annual Frontiers in Cancer Prevention Research meeting.

18 Oct 2004

Viruses from human sources occur in the La Crosse, Wisconsin municipal drinking water supply prior to its chlorination

Although the city's treated water meets or exceeds state and federal standards for drinking water, researchers and public health officials agree that more study is needed to pinpoint sources of the viruses and to determine if some viruses are surviving chlorination and making people sick with diarrhea and vomiting.

6 Oct 2004

Bristol-Myers Squibb submits New Drug Application to the U.S. Food and Drug Administration for entecavir

Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.

4 Oct 2004

Chiron grants a non-exclusive license to the German Red Cross

Chiron Corporation has announced that it has granted a non-exclusive license to the Blood Transfusion Centers of the German Red Cross (Blutspendediensten des Deutsche Rotes Kreuz, or DRK) for use of the company's HIV-1 and hepatitis C virus (HCV) technology for use in molecular probe "home brew" blood screening.

4 Oct 2004

Circulation of ‘disaster myths’ in Haiti could hinder appropriate disposal of bodies

Myths about the infectious disease threat posed by dead bodies could lead to insensitive and inappropriate treatment of victims’ bodies following the floods in Haiti, and need to be checked, according to a public health researcher who has studied the potential risks at length.

30 Sep 2004

New combination of drugs results in fewer incidences of rejection in liver transplant patients

“The big advantage [of this combination of drugs] is that the incidence of rejection is significantly decreased,” he says. “These results could change the standard of care for liver transplant recipients.”

23 Sep 2004

Research to halt the progress of chronic liver disease

A University of Queensland researcher is working to halt the progress of chronic liver disease, which affects a quarter of million Australians.

22 Sep 2004

Long-term outcomes for liver transplantation due to hepatitis C

A new study on liver transplants necessitated by the hepatitis C virus (the most common indication for this type of transplant) found that long-term outcomes are similar to patients receiving transplants due to other diseases.

8 Sep 2004

Researchers have identified multiple changes in the gene-expression patterns of cells involved with tumor progression in liver cancer patients

Virginia Commonwealth University researchers have identified multiple changes in the gene-expression patterns of cells involved with tumor progression in liver cancer patients and in those with cirrhosis, which may help scientists predict a person’s risk of developing primary liver cancer.

25 Aug 2004